The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Vivimed Labs's quick ratio for the quarter that ended in Dec. 2025 was 0.00.
Vivimed Labs has a quick ratio of 0.00. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Vivimed Labs's Quick Ratio or its related term are showing as below:
NSE:VIVIMEDLAB'
s Quick Ratio Range Over the Past 10 Years
Min: 0.58 Med: 0.72 Max: 1.29
Current: 0.66
During the past 13 years, Vivimed Labs's highest Quick Ratio was 1.29. The lowest was 0.58. And the median was 0.72.
NSE:VIVIMEDLAB's Quick Ratio is ranked worse than 82.65% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs NSE:VIVIMEDLAB: 0.66
Vivimed Labs (NSE:VIVIMEDLAB) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Vivimed Labs Quick Ratio Related Terms
Vivimed Labs Quick Ratio Historical Data
* Premium members only.
The historical data trend for Vivimed Labs's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vivimed Labs's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivimed Labs Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vivimed Labs's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Vivimed Labs's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Vivimed Labs's Quick Ratio for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivimed Labs (NSE:VIVIMEDLAB) has a Quick Ratio of 0.00 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Vivimed Labs and its competitors. Over the past decade, Vivimed Labs' Quick Ratio has ranged from 0.58 to 1.29. According to the industry distribution chart, Vivimed Labs ranks #824 out of 997 companies in the Drug Manufacturers industry, placing it in the top 82.6%.
Is Vivimed Labs' Quick Ratio too high?
Vivimed Labs' current Quick Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.58 to a high of 1.29. Based on the distribution chart, Vivimed Labs ranks #824 out of 997 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vivimed Labs has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vivimed Labs' Quick Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vivimed Labs ranks #824 out of 997 companies for Quick Ratio. This places Vivimed Labs in the lower half of its industry. The industry median Quick Ratio is 1.45. Historically, Vivimed Labs' own Quick Ratio has ranged from 0.58 to 1.29 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Vivimed Labs and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivimed Labs's current Quick Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivimed Labs stock overvalued right now?
Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.57, compared to a current price of ₹5.71 — trading 122.2% above its estimated fair value. The current Quick Ratio is 0.00. Vivimed Labs' overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current Quick Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued.
The current stock price of ₹5.71 is trading 122.2% above its estimated GF Value™ of ₹2.57.
GuruFocus considers Vivimed Labs to be Significantly Overvalued.
Key valuation signals for NSE:VIVIMEDLAB:
Quick Ratio: 0.00
GF Value™: ₹2.57 vs. price of ₹5.71 (122.2% above fair value)
No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
33GF Score
Get the complete analysis for NSE:VIVIMEDLAB
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VIVIMEDLAB has been successfully added to your 
